Biofil Chem & Pharma
Ticker > Company >

Biofil Chem & Pharma share price

Biofil Chemicals & Pharmaceuticals Ltd.

NSE: BIOFILCHEM BSE: 524396 SECTOR: Pharmaceuticals & Drugs  45.88 K   142   13

41.55
+1.29 (3.20%)
NSE: Today, 01:33 PM

Price Summary

Today's High

₹ 41.97

Today's Low

₹ 40

52 Week High

₹ 79.7

52 Week Low

₹ 40.11

FinStar is Suspended!

The FinStar rating for this company is currently unavailable due to limited data disclosure. As a micro-cap company, it may carry higher risk and limited transparency. We will update the FinStar rating once more reliable data becomes available.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 67.62 Cr.

Enterprise Value

₹ 65.77 Cr.

No. of Shares

1.63 Cr.

P/E

24.16

P/B

3.19

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  13.02

CASH

₹ 2.28 Cr.

DEBT

₹ 0.44 Cr.

Promoter Holding

46.82 %

EPS (TTM)

₹  1.72

Sales Growth

33.29%

ROE

4 %

ROCE

4.97%

Profit Growth

26.55 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year33.29%
3 Year3.85%
5 Year11.6%

Profit Growth

1 Year26.55%
3 Year-17.02%
5 Year8.02%

ROE%

1 Year4%
3 Year3.84%
5 Year5.6%

ROCE %

1 Year4.97%
3 Year5.32%
5 Year7.65%

Debt/Equity

0.0241

Price to Cash Flow

28.25

Interest Cover Ratio

21.8506

CFO/PAT (5 Yr. Avg.)

0.92086673006385

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 46.82 0.00
Mar 2025 46.82 0.00
Dec 2024 46.82 0.00
Sep 2024 46.82 0.00
Jun 2024 46.82 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company is virtually debt free.
  • Company’s PEG ratio is 0.910300777396141.
  • The company has an efficient Cash Conversion Cycle of 65.5533 days.

 Limitations

  • The company has shown a poor profit growth of -17.0240318042518% for the Past 3 years.
  • The company has shown a poor revenue growth of 3.8453920024631% for the Past 3 years.
  • Company has a poor ROE of 3.8383299804652% over the past 3 years.
  • Company has high debtor days of 244.0235.
  • The company is trading at a high PE of 24.16.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 8.44 2.41 14.2 8.35 6.43
Total Expenditure 8.14 2.29 13.89 8.24 6.43
Operating Profit 0.31 0.12 0.31 0.11 0.01
Other Income 0.03 0.02 0.02 0.24 2.83
Interest 0.01 0.01 0.01 0.01 0.01
Depreciation 0.1 0.1 0.1 0.08 0.07
Exceptional Items 0 0 0 0 0
Profit Before Tax 0.23 0.03 0.22 0.25 2.76
Tax 0.06 0.01 0.06 0.05 0.35
Profit After Tax 0.17 0.02 0.16 0.2 2.41
Adjusted EPS (Rs) 0.1 0.01 0.1 0.12 1.48

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 29.69 35.75 22.38 30.04 40.04
Total Expenditure 27.87 34.15 21.05 28.87 39.22
Operating Profit 1.82 1.6 1.33 1.17 0.82
Other Income 0.17 0.8 0.15 0.1 0.49
Interest 0.12 0.07 0.04 0.04 0.04
Depreciation 0.41 0.41 0.43 0.43 0.4
Exceptional Items 0 0 0 0 0
Profit Before Tax 1.46 1.92 1.01 0.79 0.87
Tax 0.26 0.68 0.32 0.23 0.16
Net Profit 1.21 1.24 0.7 0.56 0.71
Adjusted EPS (Rs.) 0.74 0.76 0.43 0.34 0.44

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 16.27 16.27 16.27 16.27 16.27
Total Reserves -1.39 -0.14 0.56 1.03 1.93
Borrowings 0 0 0 0 0
Other N/C liabilities 0 0.36 0.4 0.38 0.36
Current liabilities 27.48 16.75 1.49 13.73 28.52
Total Liabilities 42.36 33.24 18.73 31.41 47.08
Assets
Net Block 10.09 9.78 9.42 9 8.62
Capital WIP 0 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 0 0 0 0 0
Loans & Advances 0 0 0 0.05 0.05
Other N/C Assets 0 0 0 0 0
Current Assets 32.27 23.46 9.31 22.35 38.41
Total Assets 42.36 33.24 18.73 31.41 47.08
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 1.46 1.92 1.01 0.79 0.87
Adjustment 0.56 0.48 0.48 0.38 0.63
Changes in Assets & Liabilities -0.87 -0.62 -1.4 -1.05 1.05
Tax Paid -0.25 -0.68 -0.32 -0.23 -0.16
Operating Cash Flow 0.89 1.11 -0.22 -0.11 2.39
Investing Cash Flow -0.21 -0.1 -0.07 -0.01 -0.02
Financing Cash Flow -0.57 -0.83 -0.01 0.02 -0.12
Net Cash Flow 0.12 0.18 -0.3 -0.11 2.25

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 46.82 46.82 46.82 46.82 46.82
cyano finance and sales p... 5.39 5.39 5.39 5.39 5.39
ketan shah 2.83 2.83 2.83 2.83 3.03
kiran shah 0.39 0.39 0.39 0.39 0.39
manali simon 0.54 0.54 0.54 0.54 0.54
meena shah 3.86 3.86 3.86 3.86 3.86
meet shah 0.54 0.54 0.54 0.54 0.54
mid (india) pharmaceutica... - - - - 7.22
niyati shah 1.84 1.84 1.84 1.84 4.25
ritu shah 0.54 0.54 0.54 0.54 0.54
rohan shah 0.40 0.40 0.40 0.40 0.40
romil shah 2.35 2.35 2.35 2.35 2.35
sandeep shah 2.40 2.40 2.40 2.40 2.60
scope finance company pri... 13.90 13.90 13.90 13.90 13.90
smitesh sanalal shah 0.97 0.97 0.97 0.97 1.19
trupti shah 0.63 0.63 0.63 0.63 0.63
mid (india) pharmaceutica... 7.22 7.22 7.22 7.22 -
ramesh shah 3.04 3.04 3.04 3.04 -
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 53.18 53.18 53.18 53.18 53.18
gom industries ltd 1.11 1.11 1.11 1.11 1.11
kishor himmatsinh jhala 1.22 1.22 1.22 1.22 1.22
ksl and industries limite... 1.89 1.89 1.89 1.89 1.89
starlin equifin private l... - - - - 7.51
starline equifin private ... 7.58 7.51 7.51 7.51 -
jayesh j hapani 1.23 1.23 - - -

Annual Reports

Title Link
Title Link
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Company News

Biofil Chemicals And Pharmaceuticals informs about confirmation certificate 4 Oct, 3:43 PM Biofil Chem & Pharma - Quaterly Results 12 Aug, 7:33 PM Biofil Chem & Pharma - Quaterly Results 12 Aug, 7:33 PM Biofil Chemicals And Pharmaceuticals informs about confirmation certificate 3 Jul, 5:30 PM Biofil Chemicals & Pharmaceuticals informs about confirmation certificate 5 Apr, 12:44 PM Biofil Chem & Pharma - Quaterly Results 11 Feb, 5:30 PM Biofil Chem & Pharma - Quaterly Results 11 Feb, 5:30 PM Biofil Chem & Pharma - Quaterly Results 11 Feb, 5:30 PM Biofil Chem & Pharma - Quaterly Results 13 Aug, 6:33 PM Biofil Chem & Pharma - Quaterly Results 13 Aug, 6:33 PM Biofil Chemicals & Pharmaceuticals informs about compliance certificate 3 Apr, 5:29 PM Biofil Chemicals & Pharmaceuticals informs about disclosures 12 Mar, 5:07 PM Biofil Chem & Pharma - Quaterly Results 6 Feb, 8:47 PM Biofil Chem & Pharma - Quaterly Results 6 Feb, 8:47 PM Biofil Chemicals & Pharmaceuticals submits board meeting intimation 1 Nov, 5:08 PM Biofil Chemicals & Pharmaceuticals informs about AGM 2 Sep, 4:15 PM Biofil Chemicals And Pharmaceuticals informs about newspaper publication 24 Aug, 3:03 PM Biofil Chemicals and Pharmaceuticals informs about disclosure 24 May, 4:42 PM Biofil Chemicals & Pharmaceuticals informs about disclosure 22 Feb, 4:42 PM Biofil Chemicals & Pharmaceuticals informs about press release 15 Feb, 5:13 PM Biofil Chem & Pharma - Quaterly Results 9 Aug, 5:57 PM Biofil Chem & Pharma - Quaterly Results 9 Aug, 5:57 PM Biofil Chemicals & Pharmaceuticals informs about details of loss of certificate 7 Jul, 5:31 PM Biofil Chemicals & Pharmaceuticals informs about secretarial compliance report 26 May, 4:50 PM Biofil Chemicals & Pharmaceuticals informs about board meeting 6 Nov, 10:42 AM Biofil Chemicals & Pharmaceuticals informs about revised disclosures 22 Jul, 1:42 PM Biofil Chemicals & Pharmaceuticals informs about clarification 30 Apr, 3:36 PM Biofil Chemicals & Pharmaceuticals informs about issued duplicate share certificates 9 Mar, 1:40 PM Biofil Chemicals & Pharmaceuticals informs about disclosure 7 Jan, 5:04 PM

Biofil Chem & Pharma Stock Price Analysis and Quick Research Report. Is Biofil Chem & Pharma an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Biofil Chem & Pharma. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Biofil Chem & Pharma has a PE ratio of 23.9548810977382 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Biofil Chem & Pharma has ROA of 1.8071% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Biofil Chem & Pharma has a Current ratio of 1.3465.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Biofil Chem & Pharma has a ROE of 3.995%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Biofil Chem & Pharma has a Debt to Equity ratio of 0.0241 which means that the company has low proportion of debt in its capital.

  • Sales growth: Biofil Chem & Pharma has reported revenue growth of 33.2946% which is fair in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Biofil Chem & Pharma for the current financial year is 2.03945018521155%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Biofil Chem & Pharma is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Biofil Chem & Pharma is Rs 1.7199. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Biofil Chem & Pharma in Ticker for free. Also, one can get the intrinsic value of Biofil Chem & Pharma by using Valuation Calculators, which are available with a Finology ONE subscription. 

Biofil Chem & Pharma FAQs

Q1. What is Biofil Chem & Pharma share price today?
Ans: The current share price of Biofil Chem & Pharma is Rs 41.2.

Q2. What is the market capitalisation of Biofil Chem & Pharma?
Ans: Biofil Chem & Pharma has a market capitalisation of Rs 67.048056 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Biofil Chem & Pharma?
Ans: The PE ratio of Biofil Chem & Pharma is 23.9548810977382 and the P/B ratio of Biofil Chem & Pharma is 3.1670138595291, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Biofil Chem & Pharma share?
Ans: The 52-week high share price of Biofil Chem & Pharma is Rs 79.7, and the 52-week low share price of Biofil Chem & Pharma is Rs 40.11.

Q5. Does Biofil Chem & Pharma pay dividends?
Ans: Currently, Biofil Chem & Pharma does not pay dividends. Dividend yield of Biofil Chem & Pharma is around 0%.

Q6. What are the face value and book value of Biofil Chem & Pharma shares?
Ans: The face value of Biofil Chem & Pharma shares is Rs 10, while the book value per share of Biofil Chem & Pharma is around Rs 13.0091. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Biofil Chem & Pharma?
Ans: Biofil Chem & Pharma has a total debt of Rs 0.4389 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Biofil Chem & Pharma?
Ans: The ROE of Biofil Chem & Pharma is 3.995% and ROCE of Biofil Chem & Pharma is 4.9735%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Biofil Chem & Pharma a good buy for the long term?
Ans: The Biofil Chem & Pharma long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Biofil Chem & Pharma undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Biofil Chem & Pharma appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Biofil Chem & Pharma’s financials?
Ans: You can review Biofil Chem & Pharma’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Biofil Chem & Pharma
X